Schizophrenia Therapeutics Market 2018 - First-Generation and Second-Generation Antipsychotics Segments Analyzed at ReportsnReports.com

Share Article

Global Schizophrenia Therapeutics Market 2014-2018 is a new industry research report, of 102 Pages profiles key players like AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., H. Lundbeck A/S, Johnson & Johnson Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc. and Sumitomo Dainippon Pharma Co. Ltd.

Past News Releases

RSS

Schizophrenia is a condition in which people interpret reality abnormally. The symptoms of schizophrenia can be managed through medication and psychological therapy. Increase in aging population, increased incidences of schizophrenia and rising awareness about mental illnesses are some of the key factors which are propelling the growth of the global schizophrenia therapeutics market. Awareness about schizophrenia among physicians and patients is also going to be a major factor which will increase the demand of schizophrenia drugs in the market.

Key players in the global schizophrenia therapeutics market are Eli Lilly and Co., AstraZeneca plc, Pfizer Inc., Johnson & Johnson Ltd., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Sumitomo Dainippon Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and H. Lundbeck A/S. Some other key companies in the market include GlaxoSmithKline, Abbott Laboratories, Novartis, Merck, Acadia Pharmaceuticals, Takeda Pharmaceutical, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma, Astellas Pharma, and Alkermes plc.

One of the major challenges in the global schizophrenia therapeutics market is the increase in the generic competition. The easy availability of low-cost generic drugs intensifies the competition among vendors, substantially reducing the cost of patented or branded drugs. The Global Schizophrenia Therapeutics market can be categorized into two segments - First-generation Antipsychotics and Second-generation Antipsychotics.

This report encompasses the current and future outlook of the Global Schizophrenia Therapeutics market for the period from 2014 to 2018. The report mentions the turnover from the sales of various drugs used in the treatment of schizophrenia which are available in the market. The report Global Schizophrenia Therapeutics Market 2014-2018 provides in-depth assessment about the key market trends, key vendors, drivers, market size and forecast, and growth rate as well as market opportunities and threats faced by vendors and strengths and weaknesses of the key vendors.

Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.reportsnreports.com/purchase.aspx?name=317860.

The Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from various industry experts. The report covers the different geographical regions as well its growth prospects in the coming years.

List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Global Schizophrenia Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Schizophrenia Therapeutics Market in the US
Exhibit 4: Types of Schizophrenia
Exhibit 5: Phases of Schizophrenia
Exhibit 6: Global Schizophrenia Therapeutics Market Segmentation by Drug Class
Exhibit 7: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013
Exhibit 8: Schizophrenia Therapeutics Market in America 2013-2018 (US$ billion)
Exhibit 9: Schizophrenia Therapeutics Market in the APAC Region 2013-2018 (US$ billion)
Exhibit 10: Schizophrenia Therapeutics Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 11: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (US$ billion)
Exhibit 12: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (in percent)
Exhibit 13: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 14: AstraZeneca: Business Segmentation
Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 17: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 18: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 19: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 20: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 21: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 22: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 23: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 24: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 25: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 26: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 27: H. Lundbeck: Business Segmentation by Revenue 2013
Exhibit 28: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: H. Lundbeck: Geographical Segmentation by Revenue 2013
Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2013
And more.

Explore other new reports on Pharmaceuticals Market and other industry report by Infiniti Research Limited .

About US
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email the details on sales at reportsandreports.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@marketsreports
since: 06/2010
Follow >
ReportsnReports
since: 06/2011
Like >
Follow us on
Visit website